<DOC>
	<DOC>NCT00861692</DOC>
	<brief_summary>The purpose of this study is to collect data on the clinical management of Argatroban in patients with suspected or confirmed heparin-induced thrombocytopenia Type II, with or without ongoing thrombosis who require parenteral antithrombotic therapy</brief_summary>
	<brief_title>Clinical Management of Argatroban in Patients With Heparin Induced Thrombocytopenia Type II</brief_title>
	<detailed_description />
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Argatroban</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>Subjects aged &gt;= 18 years Females of child bearing potential must have a negative urine pregnancy test prior to entry into the study Patients with suspected or confirmed heparininduced thrombocytopenia Type II, with or without ongoing thrombosis who require parenteral anticoagulation Signed written informed consent by the subject, or if the subject is unable to do so, consent will be sought from their family member, or a trusted person nominated by the subject or the legal representative Uncontrolled bleeding Severe hepatic impairment (ChildPugh Class C) Hypersensitivity to argatroban or to any of the excipients (sorbitol and ethanol) Pregnancy (exclusion by routine urine test) Lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Argatroban</keyword>
	<keyword>heparin induced thrombocytopenia (HIT)</keyword>
	<keyword>direct thrombin inhibitor (DTI)</keyword>
</DOC>